Evidence map›Paper›PMID 39630022›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Prognostic Value of Skull Base Foramen Invasion Subclassification in T Category Modification and Induction Chemotherapy Management for Nasopharyngeal Carcinoma: Post-Hoc Analysis of a Dual-Center Retrospective Cohort Study.

Siyu Zhu, Shuqi Li, Di Cao, Chao Luo, Zhiying Liang, Shaobo Liang, Guoyi Zhang, Qin Zhao, Guangying Ruan, Lizhi Liu and 2 more

Abstract readMulticenter Study
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Siyu ZhuDepartment of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Shuqi LiDepartment of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Di CaoDepartment of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Chao LuoDepartment of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Zhiying LiangDepartment of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Shaobo LiangDepartment of Radiation Oncology, Foshan Academy of Medical Sciences, Sun Yat-Sen University Foshan Hospital and The First People's Hospital of Foshan, Foshan, 528000, P. R. China.
Guoyi ZhangDepartment of Radiation Oncology, Foshan Academy of Medical Sciences, Sun Yat-Sen University Foshan Hospital and The First People's Hospital of Foshan, Foshan, 528000, P. R. China.
Qin ZhaoDepartment of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Guangying RuanDepartment of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Lizhi LiuDepartment of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Gui FuDepartment of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Haojiang LiDepartment of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.ORCID https://orcid.org/0000-0001-5854-3989

Funding

National Natural Science Foundation of China 82171906National Natural Science Foundation of China-Regional Science Foundation Project 82260358
6 · The paper itself

Abstract

Skull base foramen invasion (SBFI) indicates poor prognosis in nasopharyngeal carcinoma (NPC). However, only a few studies systematically assessed the role of SBFIin staging and treatment of NPC. To investigate the prognostic value of SBFI in NPC, a total of 1,752 patients with nonmetastatic NPC from two hospitals (1,320 and 432) between January 2010 and March 2014 are enrolled. The primary endpoint is overall survival (OS). Heatmap/cluster and network analyses are used to provide subclassification indication. Univariate and multivariate analyses with Kaplan-Meier method are performed to compare survival outcomes. SBFIs are classified into slight (only foramen lacerum and/or pterygopalatine fossa invasion) and severe (other SBFIs). The severe SBFI is an unfavorable prognosticator for OS in both the entire cohort and the T3 group. OS is similar between T3 with severe SBFI and T4 patients. Reclassifying T3 with severe SBFI as the T4 category yields an improved T category discrimination. Additionally, patients in the severe SBFI group gain significant survival benefits from induction chemotherapy ((IC). Therefore, T3 NPC with severe SBFI is an independent negative predictor for OS and is classified into the T4 category. T category adjustment enables better prognostic stratification. Severe SBFI benefits from IC in long-term OS.

Indexed as

Induction ChemotherapyNasopharyngeal CarcinomaNasopharyngeal NeoplasmsSkull BaseAdultAgedFemaleHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPrognosisRetrospective Studiescategory modificationnasopharyngeal carcinomaskull base foramen invasiontreatment management

Identifiers

PMID39630022
PMCPMC11789575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.